Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: Early and 6 months follow-up

European Heart Journal

Volumn 29, Issue 3, 2008, Pages 348-355

  Durand, Eric ^a   Mousseaux, Elie ^a   Coste, Pierre ^b   Pillière, Rémy ^c   Dubourg, Olivier ^c   Trinquart, Ludovic ^a   Chatellier, Gilles ^a   Hagège, Albert ^a   Desnos, Michel ^a   Lafont, Antoine ^a,d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Alcohol; Coil; Complete heart block; Embolization; Hypertrophic obstructive cardiomyopathy

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COIL EMBOLIZATION; COMPLETE HEART BLOCK; ECHOCARDIOGRAPHY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; INCIDENCE; MALE; NON INVASIVE PROCEDURE; NON SURGICAL SEPTAL MYOCARDIAL REDUCTION; PRIORITY JOURNAL;

AGED; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; COHORT STUDIES; CONTRAST MEDIA; CORONARY VESSELS; EMBOLIZATION, THERAPEUTIC; EXERCISE TEST; FEASIBILITY STUDIES; FEMALE; HEART BLOCK; HEART SEPTUM; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; STENTS; TREATMENT OUTCOME;

EID: 38849205453     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm632     Document Type: Article

References (42)

1. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-214.
2. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Sigwart U. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997;95:2075-2081.
3. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998;31:252-258.
4. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn HJ. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999;20:1342- 1354.
5. Kim JJ, Lee CW, Park SW, Hong MK, Lim HY, Song JK, Jin YS, Park SJ. Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol 1999;83:1220-1223.
6. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart 2000;83:326-331.
7. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, Sachdev B, Thaman R, McKenna WJ. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 2002;23:1617-1624.
8. Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet 2000;355:425-426.
9. Seggewiss H. Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 2000;21:704-707.
10. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;38:1701-1706.
11. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363:1881-1891.
12. Hess OM, Sigwart U. New treatment strategies for hypertrophic obstructive cardiomyopathy: alcohol ablation of the septum: the new gold standard? J Am Coll Cardiol 2004;44:2054-2055.
13. Talreja DR, Nishimura RA, Edwards WD, Valeti US, Ommen SR, Tajik AJ, Dearani JA, Schaff HV, Holmes DR Jr. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol 2004;44:2329-2332.
14. Fernandes VL, Nagueh SF, Wang W, Roberts R, Spencer WH III. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy - the Baylor experience (1996-2002). Clin Cardiol 2005;28:124-130.
15. Knight CJ. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Heart 2006;92:1339-1344.
16. Ralph-Edwards A, Woo A, McCrindle BW, Shapero JL, Schwartz L, Rakowski H, Wigle ED, Williams WG. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity core. J Thorac Cardiovasc Surg 2005;129:351-358.
17. Chang SM, Nagueh SF, Spencer WH 3rd, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 2003;42:296-300.
18. Chang SM, Lakkis NM, Franklin J, Spencer WH 3rd, Nagueh SF. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 2004;109:824-827.
19. Veselka J, Prochazkova S, Duchonova R, Boloma-Homolova I, Palenickova J, Tesar D, Cervinka P, Honek T. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interv 2004;63:231-235.
20. Veselka J, Duchonova R, Prochazkova S, Palenickova J, Sorajja P, Tesar D. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol 2005;95:675-678.
21. Chen AA, Palacios IF, Mela T, Yoerger DM, Picard MH, Vlahakes G, Lowry PA, Fifer MA. Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2006;97:264-269.
22. Monakier D, Woo A, Puri T, Schwartz L, Ross J, Jamorski M, Yang H, Liu Z, Vannan M, Wigle ED, Rakowski H. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2004;94:1515-1522.
23. Lafont A, Durand E, Brasselet C, Mousseaux E, Hagege A, Desnos M. Percutaneous transluminal septal coil embolization as an alternative to alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Heart 2005;91:92.
24. Haan JM, Biffl W, Knudson MM, Davis KA, Ota T, Majercik S, Dicker R, Marder S, Scalea TM. Western Trauma Association Multi-Institutional Trials Committee. Splenic embolization revisited: a multicenter review. J Trauma 2004;56:542-547.
25. Lanzino G, Kanaan Y, Perrini P, Dayoub H, Fraser K. Emerging concepts in the treatment of intracranial aneurysms: stents, coated coils, and liquid embolic agents. Neurosurgery 2005;57:449-459.
26. Forbes TJ, Harahsheh A, Rodriguez-Cruz E, Morrow WR, Thomas R, Turner R, Turner D, Vincent JA. Angiographic and hemodynamic predictors for successful outcome of transcatheter occlusion of patent ductus arteriosus in infants less than 8 kilograms. Catheter Cardiovasc Interv 2004;61:117-122.
27. van Dockum WG, Beek AM, ten Cate FJ, ten Berg JM, Bondarenko O, Gotte MJ, Twisk JW, Hofman MB, Visser CA, van Rossum AC. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2005;111:2503-2508.
28. van Dockum WG, ten Cate FJ, ten Berg JM, Beek AM, Twisk JM, Vos J, Hofman MB, Visser CA, van Rossum AC. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 2004;43:27-34.
29. Valeti US, Nishimura RA, Holmes DR, Araoz PA, Glockner JF, Breen JF, Ommen SR, Gersh BJ, Tajik AJ, Rihal CS, Schaff HV, Maron BJ. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007;49:350-357.
30. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005;112:855-861.
31. Taylor AJ, Al-Saadi N, Abdel-Aty H, Schulz-Menger J, Messroghli DR, Gross M, Dietz R, Friedrich MG. Elective percutaneous coronary intervention immediately impairs resting microvascular perfusion assessed by cardiac magnetic resonance imaging. Am Heart J 2006;151:891.e1-7.
32. Dewey M, Laule M, Taupitz M, Kaufels N, Hamm B, Kivelitz D. Myocardial viability: assessment with three-dimensional MR imaging in pigs and patients. Radiology 2006;239:703-709.
33. Fifer MA, Yoerger DM, Picard MH, Vlahakes GJ, Palacios IF. Covered stent septal ablation for hypertrophic obstructive cardiomyopathy: initial success but ultimate failure resulting from collateral formation. Circulation 2003;107:3248-3249.
34. Anzuini A, Uretsky BF. Covered stent septal ablation for hypertrophic obstruction cardiomyopathy. Circulation 2004;109:e6.
35. Sianos G, Papafaklis MI, Vourvouri EC, Ligthart JT, Baks T, Ten Cate FJ, Serruys PW. Hypertrophic obstructive cardiomyopathy: septal ablation with overlapping sirolimus-eluting and covered stents after failed alcoholization and concomitant coronary artery disease. Circulation 2006;114:e553- e555.
36. Iacob M, Pinte F, Tintoiu I, Cotuna L, Caroescu M, Popa A, Cristian G, Goleanu V, Greere V, Moscaliuc I, Neagoe G, Crisan P, Garjeu A, Chiriac L, Bolohan R, Murgu V, Lobont B, Filip S, Roates J, Hila G, Postolea E. Microcoil embolisation for ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. Kardiol Pol 2004;61:350-355.
37. Oto A, Aytemir K, Deniz A. New approach to septal ablation: glue (cyanoacrylate) septal ablation. Catheter Cardiovasc Interv 2007;69:1021-1025.
38. Llamas-Esperon GA, Sandoval-Navarrete S. Percutaneous septal ablation with absorbable gelatin sponge in hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv 2007;69:231-235.
39. Gross CM, Schulz-Menger J, Kramer J, Siegel I, Pilz B, Waigand J, friedrich MG, Uhlich F, dietz R. Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes. J Endovasc Ther 2004;11:705-711.
40. Batalis NI, Harley RA, Collins KA. Iatrogenic deaths following treatment for hypertrophic obstructive cardiomyopathy: case reports and an approach to the autopsy and death certification. Am J Forensic Med Pathol 2005;26:343-348.
41. Wu KC, Heldman AW, Brinker JA, Hare JM, Lima JA. Microvascular obstruction after nonsurgical septal reduction for the treatment of hypertrophic cardiomyopathy. Circulation 2001;104:1868.
42. Chassaing S, Garrigoux P, Redheuil A, Blanchard D, Bar O, Maudiere A, Mousseaux E. The potential of magnetic resonance imaging for the surveillance of septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A case history. Arch Mal Coeur Vaiss 2006;99:828-831.